Core B Medicinal Chemistry

Information

  • Research Project
  • 10138977
  • ApplicationId
    10138977
  • Core Project Number
    U19AI142731
  • Full Project Number
    5U19AI142731-03
  • Serial Number
    142731
  • FOA Number
    RFA-AI-17-042
  • Sub Project Id
    7607
  • Project Start Date
    5/1/2019 - 6 years ago
  • Project End Date
    4/30/2024 - a year ago
  • Program Officer Name
  • Budget Start Date
    5/1/2021 - 4 years ago
  • Budget End Date
    4/30/2022 - 3 years ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
  • Award Notice Date
    4/19/2021 - 4 years ago

Core B Medicinal Chemistry

Abstract The Medicinal Chemistry (MedChem) Core has been formed to address the urgent need for novel antibacterial agents. The MedChem Core will work seamlessly with the Project Teams and other Cores to drive the time- and cost-efficient discovery and development of novel lead compounds to target high-threat bacterial infections. Critical to its mission are its competencies in industrial and academic medicinal chemistry, cheminformatics, and structural biology, which are complemented by decades of experiences with the fundamental biology of the relevant bacterial agents. The MedChem Core will aid in the confirmation of hits discovered through computation or experimental screens, evolve these to early and then optimized leads following a defined workflow with quantitative metrics for molecules at each stage in the process. The MedChem Core will collaborate on projects focused on the discovery and development of A) phloroglucinol and myxopyronin antibacterials, B) rifamycin and oxazolidinone agents against Mycobacterium abscessus, C) antituberculars targeting cell wall biosynthesis or respiration, D) antibiotics suggested by mining of biosynthetic gene clusters, and E) bacterial cell envelope biogenesis inhibitors to prevent Gram-negative multi-drug resistant infections.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    U19
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    929960
  • Indirect Cost Amount
    0
  • Total Cost
  • Sub Project Total Cost
    929960
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIAID:929960\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    HACKENSACK UNIVERSITY MEDICAL CENTER
  • Organization Department
  • Organization DUNS
    042797571
  • Organization City
    HACKENSACK
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    076011915
  • Organization District
    UNITED STATES